Publications

High-throughput functional siRNA screening in ovarian cancer cell lines identified that tyrosine kinase with immunoglobulin-like and EGF-like domains 1, TIE-1 confers resistance to cisplatin and could be a potential therapeutic target for platinum resistant ovarian cancer. 

Studies conducted by CTD2 scientists at Oregon Health and Science University have shown that combined inhibition of JAK1/2 and BCL2 as a potential therapeutic option for acute myeloid leukemia (AML) patients.

Review on the role of CDK12 as a clinical biomarker and as a potential therapeutic target for cancer therapy.

CTD2 researchers at UCSF showed that SHP2, a non-receptor protein tyrosine phosphatase, could be a potential molecular target in cancers driven by oncogenic mutants of RAS/MAPK pathway.

A review article on using the patient-derived cancer models for the identification of targets to overcome roadblocks of precision oncology.

Genome-scale open reading frame screen identifies RNA binding proteins, QK1 and RBFOX1, regulate the alternate splicing of actin binding protein, FLNB. The skipping of FLNB exon 30 is associated with the transition to mesenchymal- and stem-like cell states in breast cancer pathogenesis.